Surface Oncology licenses anti-cancer antibody from Vaccinex

By The Science Advisory Board staff writers

February 22, 2021 -- Surface Oncology will exercise an option to license the anti-C-C motif chemokine receptor 8 (CCR8) antibody discovered using the ActivMab antibody discovery and novel viral display platform from Vaccinex.

The antibody, SRF114, is a fully human immunoglobulin G1 (IgG1) anti-CCR8 antibody that selectively depletes immunosuppressive tumor T regulatory cells (Tregs) while sparing peripheral Tregs.

The ActivMab platform is a proprietary mammalian cell-based antibody discovery and viral display platform that can be used for discovery of antibodies specific for complex membrane antigens, discovery of antibodies with optimized developability, and protein optimization for expression and activity, according to Vaccinex.

Under the agreement, Surface Oncology will pay technology access and licensing fees in addition to research funding of an undisclosed amount. Vaccinex will also qualify for development and milestone payments and royalties on the product.

GSK licenses cancer immunotherapy from Surface Oncology
GlaxoSmithKline (GSK) has obtained an exclusive license worldwide and commercial rights to Surface Oncology's preclinical program, SRF813, an antitumor...

Copyright © 2021

Cell Bio 2022
December 3-7
District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter